Acinetobacter bereziniae clinical relevance is starting to be recognized; however, very few descriptions of its carbapenem resistance currently exist. Here we characterize two carbapenem-resistant A. bereziniae isolates. materials & methods: Isolates were obtained from environmental and clinical samples. Carbapenemases were searched by phenotypic, biochemical and PCR assays. Clonality was studied by ApaI-PFGE and genetic location for carbapenemase genes were assessed by I-CeuI and S1 hybridizations. results: Isolates were not clonally related but both produced the 'exclusively Portuguese' IMP-5, with the clinical isolate also producing an OXA-58. The carbapenemase genes were plasmid located. Conclusion: Our results emphasize the role of non-baumannii Acinetobacter species as important reservoirs of clinically relevant resistance genes that could also contribute to their emergence as nosocomial pathogens.
Metallo-β-lactamases (MBLs) currently represent an important and emerging mechanism of acquired-carbapenem resistance in Gram-negative bacteria, responsible for difficult-to-treat nosocomial infections, and are consequently associated with both high morbidity and mortality rates. Enzymes belonging to VIM and IMP families are among the most prevailing MBLs, rapidly growing and conferring the greatest clinical threat. Thus far, the IMP-5 MBL has only been described in Portugal, initially in an Acinetobacter baumannii clinical isolate belonging to the sequence type (ST) 120 and posteriorly in Pseudomonas aeruginosa clinical isolates [1] [2] [3] . The bla IMP-5 gene was described as part of the class 1 integron In76, located on a Tn402-like transposon, with two miniature inverted-repeat transposable elements (MITE)-like flanking the 5′CS to 3′CS regions [1, 2] . This structure, also associated with other resistance determinants, such as bla PER-1 in Acinetobacter johnsonii, represents a mobilizable unit which might be responsible for intra-and interspecies transfer, via transposition or homologous recombination [2, 3] . Notwithstanding, the reservoir of the 'exclusively Portuguese' bla gene is yet to be known.
Within the last decades, Acinetobacter species have, surprisingly and successively, evolved from traditionally harmless organisms into important nosocomial pathogens exhibiting high levels of antibiotic resistance, including extreme drug resistance [4, 5] . Acinetobacter bereziniae (formerly For reprint orders, please contact: reprints@futuremedicine.com Acinetobacter genomospecies 10) is presently considered one of the non-baumannii Acinetobacter emerging pathogenic species [6] . Descriptions of this species include vegetable samples [7] , fecal carriage among healthy humans [8] and different human clinical specimens, suggesting its wide distribution [9] . More recently, it has also been associated with chronic obstructive pulmonary disease, urinary tract infection, pneumonia, sepsis and bacteremia [6, [10] [11] . Reports on carbapenem resistance in A. bereziniae were previously associated with the production of IMP-1 and IMP-19, SIM-1, VIM-2 and NDM-1 MBLs [10] [11] [12] [13] . Additionally, two variants of the intrinsic oxacillinase OX A-228-like, OX A-229 and OXA-257, able to confer carbapenem resistance when overexpressed, were recently described in A. bereziniae [14, 15] . This report aims the characterization of two A. bereziniae isolates obtained in the same hospital, from the water of a newborn incubator's humidity chamber and from a blood culture, which exhibited an unusual multidrug resistance phenotype, including resistance to carbapenems.
materials & methods
Two A. bereziniae isolates, obtained at an interval of 4 years in the same University Hospital in Portugal, were studied. Acinetobacter bereziniae HGSA93 was collected in 2008 from the water reservoir of a new-born's incubator humidity system, while A. bereziniae HGSA593 was obtained in 2012 from a blood culture of a hospitalized patient with chronic renal disease. Isolates were initially identified as Acinetobacter lwoffii by the vitek 2 system. Further identification included rpoB gene partial sequencing [16] and PCR searching for Acinetobacter species-specific oxacillinase, OXA-228-like, using previously described primers [14] .
Antibiotic susceptibility testing was performed by disc diffusion method and E-test following CLSI guidelines [17] . Carbapenemase production was assessed by the Blue-Carba test [18] . Furthermore, isolate crude extracts were used to conduct a bioassay with imipenem (with and without EDTA).
Acquired carbapenemase genes (MBL and carbapenem-hydrolyzing class D β-lactamases [CHDL]) were searched by PCR using primers and conditions as previously described [1, 19] , and confirmed by sequencing. Class 1 integrons were searched with primers directed for 5′CS and 3′CS regions [20] and confirmed by sequencing. Additionally, association of the MBL genes with the Tn402-like transposon (GenBank accession number JF810083) was investigated by PCR mapping with a combination of primers for the MBL gene [1] , orf5 [21] and MITEs sequences (MITE_Fw_2: 5′-GATA ACCA ATCCATTTATGACA-3′; MITE_Rv_2: 5′-TGACTGACCATTA A A-GTCTCAA-3′).
The carbapenemase genes location was assessed by hybridization of I-CeuI-and S1-digested genomic DNA with specific probes for the carbapenemases and 16S rRNA genes. Plasmid characterization was performed using the PCR-based replicon typing scheme for A. baumannii plasmids [22] .
Transfer of carbapenemase genes was attempted by conjugation with rifampicinresistant mutant of A. baumannii ATCC 17978 (kindly provided by Dr Ruth Hall), and by electrotransformation with the plasmid DNA from HGSA593 isolate, using Acinetobacter baylyi ADP1 (kindly provided by Dr German Bou), as the recipient strain. Selection was performed on Mueller-Hinton agar plates supplemented with imipenem (0.5 mg/l) and rifampicin (100 mg/l) for conjugation assays and only with imipenem (0.5 mg/l) for electrotransformation. Presumptive transformants were confirmed by searching carbapenemases genes by PCR.
Clonal relatedness for the two isolates was assessed by genomic DNA macrorestriction with T GenBank accession number JQ422053.1) and presented the same promoter sequences (TTCAAT and TGGTAT for the -35 and -10 sequences, respectively) that have been related with its low expression [14, 15] .
Both isolates presented an unusual antibiotic resistance profile that included resistance to all tested β-lactams. HGSA93 remained susceptible to aminoglycosides (except kanamycin), while HGSA593 was only susceptible to amikacin (table 1) . Blue-carba test revealed the presence of carbapenemase activity and the bioassay with EDTA strongly suggested the presence of an MBL, further identified as IMP-5 in both isolates by PCR and sequencing. Search for acquired CHDL revealed that HGSA593 also harbored bla OX A-58 , which is a carbapenemase that had been endemic within this hospital among A. baumannii clinical isolates and disappeared after 2006 [5] . Sequencing of the bla IMP-5 -encoding class 1 integron, from HGSA93, revealed 100% homology with the previously described In76 [1] and its nucleotide sequence was deposited in the GenBank database (accession number KF732850.1). PCR mapping showed that this genetic platform was also flanked by MITE structures, a fact that might justify bla IMP-5 gene mobilization [2, 3] . Curiously, sequence analysis indicated the presence of a weak -35 promoter (TTGACA instead of TTGATA) upstream bla IMP-5 gene [23] , contrary to what was expected by the observed high carbapenem resistance level (table 1) . HGSA593 harbored similar genetic vicinity for bla , but the integron content included an extra gene cassette (bla OXA-4 ) downstream bla IMP-5 gene. Moreover, HGSA593 harbored another class 1 integron carrying an aacA4 gene, which might explain its additional resistance to aminoglycosides. I-CeuI-and S1 hybridizations revealed that bla IMP-5 gene was located in a ∼310 Kb plasmid for HGSA93 and in a ∼200 Kb plasmid for HGSA593 (Figure 1) and bla OXA-58 was located in a ∼90 Kb additional plasmid. These plasmids were untypeable using the current replicon typing scheme [22] , which is now commonly reported among non-baumannii Acinetobacter species [24] . Conjugation attempts were unsuccessful, but plasmids from HGSA593 were transferred and expressed in A. baylyi ADP1, with transformants exhibiting resistance to β-lactams, including carbapenems (table 1) .
Curiously, ApaI-PFGE assay revealed that A. bereziniae isolates were unrelated (Figure 1) , suggesting that this species might easily acquire different plasmids and act as reservoir of clinically relevant resistance genes.
Conclusion
Our data highlight the ability of non-baumannii Acinetobacter species to acquire relevant resistance genes which could contribute for their emergence as nosocomial pathogens. Furthermore, cumulative findings suggest that different species of Acinetobacter seem to constitute important reservoirs of resistance genes outside clinical settings. In this study, although the first A. bereziniae isolate was not associated with any infection episode, its detection in the newborn's incubator humidity chamber, along with the second bloodstream isolate and previous works on this species, should indicate the possibility of 'environmental' species emerge as etiologic agents of nosocomial infections, particularly within vulnerable populations.
Finally, we believe that further studies focused on the local microbial ecology of carbapenemase producers are imperative for the full understanding of the observed endemicity of IMP-5 in our country and for the effective prevention of its dissemination. 
Financial & competing interests disclosure

exeCutive summary
• We extended the species reservoir of the 'exclusively Portuguese' IMP-5 carbapenemase.
• Environmental Acinetobacter bereziniae isolates could act as reservoirs for bla IMP-5 .
• Newborn incubator systems could be a source of carbapenemase producing Acinetobacter spp.
• We confirm the pathogenic potential of carbapenem-resistant A. bereziniae. 
